<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6896476</article-id><article-id pub-id-type="pmid">31790602</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1698036</article-id><article-id pub-id-type="publisher-id">1698036</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Benzothiazole derivatives as anticancer agents</article-title><alt-title alt-title-type="left-running-head">A. Irfan et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Irfan</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Batool</surname><given-names>Fozia</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Zahra Naqvi</surname><given-names>Syeda Andleeb</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Islam</surname><given-names>Amjad</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Osman</surname><given-names>Sameh M.</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><name><surname>Nocentini</surname><given-names>Alessio</given-names></name><xref ref-type="aff" rid="AF0004">d</xref></contrib><contrib contrib-type="author"><name><surname>Alissa</surname><given-names>Siham A.</given-names></name><xref ref-type="aff" rid="AF0005">e</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4262-0323</contrib-id><name><surname>Supuran</surname><given-names>Claudiu T.</given-names></name><xref ref-type="corresp" rid="AN0002"/><xref ref-type="aff" rid="AF0004">d</xref></contrib><aff id="AF0001"><label>a</label><institution>Department of Chemistry, University of Lahore</institution>, <city>Sargodha</city>, <country>Pakistan</country></aff><aff id="AF0002"><label>b</label><institution>College of Materials Engineering, Fujian Agriculture and Forestry University</institution>, <city>Fuzhou</city>, <country>P.R. China</country></aff><aff id="AF0003"><label>c</label><institution>Chemistry Department, College of Science, King Saud University</institution>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="AF0004"><label>d</label><institution>NEUROFARBA Department, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence</institution>, <city>Sesto Fiorentino (Firenze)</city>, <country>Italy</country></aff><aff id="AF0005"><label>e</label><institution>Chemistry Department, College of Science, Princess Nourah bint Abdulrahman University</institution>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Ali Irfan <email>aliirfanrai@hotmail.com</email><institution>Department of Chemistry, University of Lahore</institution>, <addr-line>Sargodha Campus</addr-line>, <city>Sargodha</city>, <country>Pakistan</country>; </corresp><corresp id="AN0002">Claudiu T. Supuran <email>claudiu.supuran@unifi.it</email><institution>NEUROFARBA Department, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence</institution>, <addr-line>via Ugo Schiff 6</addr-line>, <postal-code>50019</postal-code>, <city>Sesto Fiorentino (Firenze)</city>, <country>Italy</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>2</day><month>12</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><volume>35</volume><issue>1</issue><fpage seq="27">265</fpage><lpage>279</lpage><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_35_1698036.pdf"/><abstract><title>Abstract</title><p>Benzothiazole (BTA) belongs to the heterocyclic class of bicyclic compounds. BTA derivatives possesses broad spectrum biological activities such as anticancer, antioxidant, anti-inflammatory, anti-tumour, antiviral, antibacterial, anti-proliferative, anti-diabetic, anti-convulsant, analgesic, anti-tubercular, antimalarial, anti-leishmanial, anti-histaminic and anti-fungal among others. The BTA scaffolds showed a crucial role in the inhibition of the metalloenzyme carbonic anhydrase (CA). In this review an extensive literature survey over the last decade discloses the role of BTA derivatives mainly as anticancer agents. Such compounds are effective against various types of cancer cell lines through a multitude of mechanisms, some of which are poorly studied or understood. The inhibition of tumour associated CAs by BTA derivatives is on the other hand better investigated and such compounds may serve as anticancer leads for the development of agents effective against hypoxic tumours.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Benzothiazole</kwd><kwd>anticancer agent</kwd><kwd>drug targets</kwd><kwd>scaffold</kwd><kwd>carbonic anhydrase inhibitor</kwd></kwd-group><counts><fig-count count="43"/><table-count count="0"/><page-count count="15"/><word-count count="8890"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Heterocyles are important pharmcophores and have significance to create privileged chemical structures possessing pharmacological activities. Five membered heterocyclic which incorporate oxygen, nitrogen and sulphur are found in broad spectrum therapeutic agents which have an enormous significance in drug discovery and drug development processes<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. Benzothaizole (BTA) is a fused benzoheterocyle which is present in many naturally occurring products and is responsible for the medicinal, pharmacological and pharmaceutical applications of such natural products<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. BTA is present in terrestrial as well as marine compounds which exhibit various biological activities<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>. The BTA nucleus is formed by the fusion of the thiazole ring with a benzene ring<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>.</p><p>The pharmacological profile of the drug used for the management of amyotrophic lateral sclerosis Riluzole (<xref ref-type="fig" rid="F0001">Figure 1</xref>) attracted the attention of medicinal chemists towards biologically active benzothiazole<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Structure of riluzole, a drug for amyotrophic lateral sclerosis.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0001_B"/></fig><p>The BTA scaffold possesses a wide spectrum of biological activities such as anti-inflammatory<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>, fungicidal<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>, anti-diabetic<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>, analgesic<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>, anti-microbial<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref>, antitumor<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref>, antileishmanial<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>, antheltmintic<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>, antirheumatic<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref> and CNS depressant<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref> etc. BTA derivatives exhibit remarkable and prevalent biological and pharmacological activities against different types of tumours and cancer cell lines such as HeLa (human cervical cancer cell line), SW480 (human colon adenocarcinoma cell line), HepG2 (human liver carcinoma cells)<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>, mammary and ovarian tumour cell lines<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>, colon, nonsmall-cell lung and breast subpanels cell lines<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref>, and HCC (hepatocellular carcinoma)<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref> etc.</p><p>Cancer is the most prominent, notably complex and lethal disease which became a serious concern of today&#x02019;s medical science. It poses a great challenge to medical scientific community for development of drugs, medicines and procedures for safer treatment and cure of cancer disease<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. These neoplasm tumour cells are diversified, heterogeneous cells with rapid proliferative properties. These neoplasm malignant tumours, have potential to invade or spread to other parts of body through blood stream and lymphatic system<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>. The plethora of research mentioned in the present review of last decade on anticancer potential of BTA derivatives will be helpful in future drug discovery and drug development for the treatment of lethal cancer disease.</p></sec><sec id="S0002" disp-level="1"><label>2.</label><title>BTA derivatives as anticancer agents</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Fluorinated derivatives of benzothiazole as anticancer agents</title><p>Aiello et&#x000a0;al. synthesised fluorinated 2-aryl benzothiazole derivatives and evaluate them for anti-tumour activities against cancer cell lines such as MDA-MB-468 (mammary gland/breast tissues derived from metastatic site) and MCF-7 cell line (human breast adenocarcinoma). The fluorinated BTA derivatives <bold>1</bold> (3&#x02013;(5-fluorobenzo[d]thiazol-2-yl)phenol) and <bold>2</bold> (4&#x02013;(5-fluorobenzo[d]thiazol-2-yl)phenol) having hydroxyl substituents on the third and fourth position of phenyl exhibited the best activity having GI<sub>50</sub> values of 0.57 and 0.4&#x02009;&#x000b5;M respectively against MCF-cell line as compared to BTA derivatives containing alkoxy, methyl sulphonyl and ethyl substituents on the benzothiazole (<xref ref-type="fig" rid="F0002">Figure 2</xref>). Kumbhare et&#x000a0;al. afforded the <italic>N</italic>-bis-benzothiazole and benzothiazolyl thiocarbamide derivatives and screened for cytotoxic activities against two human cell lines U-937 (human macrophage cell line), THP-1 (human leukaemia monocytic cell line) and B16-F10 (mouse melanoma cell line). The thiourea containing benzothiazole derivative <bold>3</bold> (<xref ref-type="fig" rid="F0003">Figure 3</xref>) demonstrated the best antiproliferative activity against the U-937 cell line as compared to standard drug Etoposide. The IC<sub>50</sub> values of compound <bold>3</bold> were higher (16.23&#x02009;&#x000b1;&#x02009;0.81&#x02009;&#x000b5;M)), (4847.73&#x02009;&#x000b1;&#x02009;2.39&#x02009;&#x000b5;M)) and (34.58&#x02009;&#x000b1;&#x02009;1.73&#x02009;&#x000b5;M)) as compared to standard compound etoposide IC<sub>50</sub> values (17.94&#x02009;&#x000b1;&#x02009;0.89), (18.69&#x02009;&#x000b1;&#x02009;0.94) and (2.16&#x02009;&#x000b1;&#x02009;0.11&#x02009;&#x000b5;M)) against U-937, B16-F10 and THP-1 cell lines respectively<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Substituted phenols containing a flourobenzothiazol scaffold <bold>1</bold> and <bold>2</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0002_B"/></fig><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Substituted thiourea containing benzothiazole derivative <bold>3</bold> and the <bold>s</bold>ubstituted pyrrolidine based imidazo benzothiazole derivative <bold>4</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0003_B"/></fig><p>Kumbhare et&#x000a0;al. reported the synthesis of mannich base arylimidazo derivatives containing benzothiazole moiety and screened for their anticancer activities against HepG2, MCF -7 and HeLa cell lines. All these synthesised mannich bases BTA scaffolds showed cytotoxicity against all tested cell lines but the pyrrolidine based imidazo benzothiazole derivative <bold>4</bold> (<xref ref-type="fig" rid="F0003">Figure 3</xref>) demonstrated specific features of apoptosis as enhancement in the levels of caspase-3. The compound <bold>4</bold> exhibited anti cancer activity and proved to be the best antiproliferative agent as compared to other derivatives against HepG2, MCF-7 and HeLa cell line when screened at 4.0&#x02009;&#x000b5;M concentrations. The SAR studies revealed that the incorporation of fluorine atom at the 7<sup>th</sup> position of derivative <bold>4</bold> enhanced the cytotoxicity. The compound <bold>4</bold> have potential to lead in the treatment of cancer especially against hepatocaricinoma. The anticancer activity potential of BTA scaffold <bold>4</bold> is encourging for the development of new anti-cancer therapeutic agents and this will be good addition in armamentarium that consists of paclitaxel, cisplatin and doxorubicin drugs<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>.</p><p>Caputo et&#x000a0;al. afforded two types of five derivatives on the basis of an aryl amide and an aryl urea functionalities attached at C-2 of benzothiazole core and these scaffolds were screened against 60 human cancer cell lines. The urea moiety based fluorophenyl containing benzothiazole derivative <bold>4</bold> (<xref ref-type="fig" rid="F0003">Figure 3</xref>) and cyanophenyl containing benzothiazole derivative <bold>5</bold> (<xref ref-type="fig" rid="F0004">Figure 4</xref>) demonstrated remarkable anticancer activities. The BTA derivative <bold>4</bold> exhibited the anticancer activity at 10<sup>&#x02212;5&#x02009;</sup>M against different cell lines such as leukaemia cell lines (log GI<sub>50</sub> value &#x02212;5.48), non-small cell lung cell lines (log GI<sub>50</sub> value &#x02212;5.48), colon cancer cell lines (log GI<sub>50</sub> value &#x02212;5.51), central nervous system cancer cell lines (log GI<sub>50</sub> value &#x02212;5.49), melanoma cell lines (log GI<sub>50</sub> value &#x02212;5.48), ovarian cancer cell lines (log GI<sub>50</sub> value &#x02212;5.49), renal cancer cell lines (log GI<sub>50</sub> value &#x02212;5.53), prostate cancer cell lines (log GI<sub>50</sub> value &#x02212;5.50) and breast cancer cell lines (log GI<sub>50</sub> value &#x02212;5.56) in comparison with reference drug 5-fluorouracil NSC 19893. The BTA scaffold <bold>5</bold> showed remarkable growth inhibitory activities against different human tumour cell lines such as leukaemia cell lines (log GI<sub>50</sub> value &#x02212;5.93), non-small cell lung cell lines (log GI<sub>50</sub> value &#x02212;6.0), colon cancer cell lines (log GI<sub>50</sub> value &#x02212;5.89), central nervous system cancer cell lines (log GI<sub>50</sub> value &#x02212;5.73), melanoma cell lines (log GI<sub>50</sub> value &#x02212;5.89), ovarian cancer cell lines (log GI<sub>50</sub> value &#x02212;5.74), renal cancer cell lines (log GI<sub>50</sub> value &#x02212;5.90), prostate cancer cell lines (log GI<sub>50</sub> value &#x02212;5.72) and breast cancer cell lines (log GI<sub>50</sub> value &#x02212;6.0) as compared with reference drug 5-fluorouracil NSC 19893. The scaffolds <bold>4</bold> and <bold>5</bold> showed the best anticancer therapeutic potential due to presence of electron with drawing groups on <italic>para</italic> position of phenyl ring<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Substituted fluorophenyl containing benzothiazole urea derivative <bold>5</bold> and 2-substituted cyanophenyl containing benzothiazole urea derivatives <bold>6</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0004_B"/></fig><p>El-Damasy et&#x000a0;al. synthesised the novel amide and urea based BTA series of 20 sorafenib analogues in which the pyridylamide privileged functionality was attached with an ether linkage at 6-position of the BTA ring. A selected group of 12 potent scaffolds were evaluated and appraised for anti-proliferative activities against sixty human cancer cell lines. These chlorotrifluoromethyl phenyl ureido picolinamide benzothiazoles <bold>7</bold> (<xref ref-type="fig" rid="F0005">Figure 5</xref>), bis-trifluoromethyl phenyl ureido based picolinamide benzothiazole derivative <bold>8</bold> (<xref ref-type="fig" rid="F0005">Figure 5</xref>) and dichlorophenyl ureido based picolinamide benzothiazoles <bold>9</bold> (<xref ref-type="fig" rid="F0005">Figure 5</xref>) were more potent in the treatment of renal cell carcinoma than the standard drug sorafenib, used for the treatment of such tumours. The 3,5-bis-trifluoromethylphenylurea <bold>8</bold> showed good inhibitory activities against ACHN (renal cancer cells lines) and A-498 (human kidney carcinoma cell line) with GI<sub>50</sub> values of 0.542&#x02009;&#x000b5;M and 1.02&#x02009;&#x000b5;M respectively. This compound also possess efficacy against UO-31 and RXF 393 cell lines. The derivatives <bold>7</bold> and <bold>9</bold> because of 3,4-disubstitutedphenyl moiety, exhibited excellent anti-proliferative activities with low IG<sub>50</sub> values of 1.85, 2.10&#x02009;&#x000b5;M against RCC and ACHN cell lines respectively. The SAR study revealed the fact that sorafenib analogues possesses anti proliferative activity due to the presence of both urea spacer and phenyl disubstitution. Compound <bold>8</bold> demonstrated the highest CLogP value being the most lipophilic and potent derivative, in the low &#x000b5;M range<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref>.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Derivative <bold>7</bold>&#x02013;<bold>9</bold> discussed in the paper.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0005_B"/></fig><p>Ma et&#x000a0;al. reported BTA derivatives containing an <italic>ortho</italic>-hydroxy-N-acyl hydrazone moiety for antiproliferative activities and procaspase-3 kinase activation activities against five different cell lines, namely MDA-MB-231 (human breast adenocarcinoma cell line), MNK-45 (gastric cancer cell line), NCI-H226 (human lung cancer cell line), HT-29 (human colorectal adenocarcinoma cell line) and SK-N-SH (neuroblastoma cell line). The substituted 2-hydroxybenzylidene containing semicarbazide <bold>10</bold> (<xref ref-type="fig" rid="F0006">Figure 6</xref>) showed inhibitory activities against all cell lines with IC<sub>50</sub> and EC<sub>50</sub> values ranging from 0.24 to 0.92&#x02009;&#x000b5;M and 0.31&#x02009;&#x000b5;M respectively. The SAR studies revealed the paharmacological activities of BTA scaffold <bold>10</bold> in <italic>in-vitro</italic> is due to introduction of phenyl and benzyloxyl substitutions<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Benzothiazoles <bold>10</bold> and <bold>11</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0006_B"/></fig><p>Gabr et&#x000a0;al. obtained hydrazine derivatives by treating 2-amino-6-fluorobenzothiazole with hydrazine hydrate which was further treated with the suitable aldehydes to afford 27 different BTA Schiff base derivatives. These derivatives were screened for anti-tumour potential against Hela (cervical cancer) and COS-7 (kidney fibroblast cancer) cell lines. The hydrazine based benzothiazole <bold>11</bold> (<xref ref-type="fig" rid="F0006">Figure 6</xref>) exhibited IC<sub>50</sub> of 2.41&#x02009;&#x000b5;M and 4.31&#x02009;&#x000b5;M against Hela and COS-7 cell lines as compared to reference doxorubicin having IC<sub>50</sub> 2.05&#x02009;&#x000b5;M and 3.04&#x02009;&#x000b5;M respectively. The SAR studies explained the effect of various substitutions on activities of all the synthesised derivatives. The scaffold present in <bold>11</bold> has the 2&#x02013;(4-hydroxy-methoxy benzylidene)-hydrazino moiety at the C-2 position which remarkably enhances the anti-tumour potential, whereas replacing the 4-hydroxy moiety with 4-methoxy decreased the activities against both cell lines<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>.</p><p>Junjie et&#x000a0;al. reported the synthesis of semicarbazone containing BTA derivatives by the reaction of 4-nitrobenzyl bromide with substituted amines under different reaction conditions and evaluated their anticancer activity against four different cancer cell line such as human colon cancer cells (HT29), human lung cancer cell (H460), non-small cell lung cancer (A549) and human breast cancer (MDA-MB-231). Among these derivatives, the indole based hydrazine carboxamide scaffold <bold>12</bold> (<xref ref-type="fig" rid="F0007">Figure 7</xref>) showed potent antitumor activity with IC<sub>50</sub> values of 0.015&#x02009;&#x000b5;M for HT29, 0.28&#x02009;&#x000b5;M for H460, 1.53&#x02009;&#x000b5;M for A549 and 0.68&#x02009;&#x000b5;M for MDA-MB-231. The structure &#x02013; activity relationship explained that compound <bold>12</bold> exhibited the highest antitumor activity due to the presence of electron withdrawing groups in the 4 position of benzyl ring<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref>.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Indol based hydrazine carboxamide benzothiazole derivative <bold>12</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0007_B"/></fig></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Imidazole based benzothiazole derivatives as anticancer agents</title><p>Yurttas et&#x000a0;al. obtained 2&#x02013;(4-aminophenyl)BTA derivatives substituted with different heterocyclic rings and tested their antitumor potential against 60 human tumour cell lines. The BTA derivatives <bold>13</bold> (2&#x02013;(1<italic>H</italic>-benzo[d]imidazol-2-ylthio)-<italic>N</italic>-(4-(benzo[d]thiazol-2-yl)-3-chlorophenyl) acetamide) (<xref ref-type="fig" rid="F0008">Figure 8</xref>) and <bold>14</bold> (<italic>N</italic>-(4-(benzo[d]thiazol-2-yl)phenyl)-2-(1-phenyl-1<italic>H</italic>-benzo[<italic>d]</italic>imidazol-2-yl-thio)-acetamide) (<xref ref-type="fig" rid="F0008">Figure 8</xref>) showed remarkable antitumor potential against different cancer cell lines. The heterocylic substitutions affect the activity and antitumor potential of these BTA derivatives, with derivative <bold>14</bold> having comparable antitumor potential with the standard drugs whereas derivative <bold>13</bold> being less active compared to <bold>14</bold>. The order overall antitumor potential of 2&#x02013;(4-aminophenyl) benzothiazole derivatives with reference to the heterocyclic substitution was benzimidazole <inline-formula id="ilm0001"><alternatives><inline-graphic xlink:href="IENZ_A_1698036_ILM0001.jpg"/><mml:math id="d2e629"><mml:mo>&#x02265;</mml:mo></mml:math></alternatives></inline-formula> imidazole&#x02009;&#x0003e;&#x02009;benzothiazole&#x02009;&#x0003e;&#x02009;benzoxazole<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref>.</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>Substituted phenyl imidazole based benzothiazoles <bold>13</bold> and <bold>14</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0008_B"/></fig><p>Singh et&#x000a0;al. reported the synthesis of imidazole based benzothiazoles by treatment of substituted anilines with KSCN which afforded the desired benzothiazole derivatives, and studied their anticancer activities. Compound <bold>15</bold> (<xref ref-type="fig" rid="F0009">Figure 9</xref>) showed excellent anticancer activity possessing IC<sub>50</sub> value 10&#x02009;&#x000b5;M when compared with the standard drug doxorubicin<xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref>.</p><fig id="F0009" orientation="portrait" position="float"><label>Figure 9.</label><caption><p>Imidazole based benzothiazole derivative <bold>15</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0009_B"/></fig></sec><sec id="S0002-S2003" disp-level="2"><label>2.3.</label><title>Piperazine based benzothiazole derivatives as anticancer agents</title><p>Al-Soud. et&#x000a0;al. reported the synthesis of BTA derivatives incorporating sulphonamide, piperazino-arylsulfonamide and arylthiol scaffolds and determined their anti-proliferative potential against different cell lines, such as CCRF-SB (Human acute B-lymphoblastic leukaemia), DU-145 (human prostate cancer cell lines express androgen receptor), HepG-2 cell line (human liver cancer), WIL-2NS (Human splenic B-lymphoblastoid cells), MRC-5 (human lung fibroblast cell line), MCF-7 cell line (human breast adenocarcinoma), MT-4 (human T-cells containing an integrated HTLV-1 genome), SK-MES-1 cell line (human lung cancer) and SK-28 cell line (skin melanoma). Derivative <bold>16</bold> (<italic>N</italic>-(2&#x02013;(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)-2-oxoethyl)-4-chloro-benzenesulfonodithioamide) showed antiproliferative activity (CC<sub>50</sub> = 8&#x02009;&#x000b1;&#x02009;3&#x02009;&#x000b5;M) against human derived DU-145 cell line (<xref ref-type="fig" rid="F0010">Figure 10</xref>) whereas derivative <bold>17</bold> (<italic>N</italic>-(2&#x02013;(4-(benzo[d]thiazol-2-yl) piperazin-1-yl)-2-oxoethyl)-2,5-dichloro benzenesulfonodithio-amide) demonstrated remarkable activities against several human derived cell lines such as HepG2 and DU-145 (with CC<sub>50</sub> of 8&#x02009;&#x000b1;&#x02009;2&#x02009;&#x000b5;M, and 9&#x02009;&#x000b1;&#x02009;2&#x02009;&#x000b5;M, respectively) (<xref ref-type="fig" rid="F0010">Figure 10</xref>). Derivatives <bold>16</bold> and <bold>17</bold> exhibited atiproliferative potential due to the introduction of chloro and dichloro phenyl groups while their replacement of with hydrogen, methoxy, nitro, triflouromethyl and methyl groups lead to a decrease in the antiproliferative potential of BTA derivatives<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref>.</p><fig id="F0010" orientation="portrait" position="float"><label>Figure 10.</label><caption><p>Di-/monochlorobenzenesulfonamide based piperazine benzothiazoles derivative <bold>16</bold> and <bold>17</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0010_B"/></fig><p>Gurdal et&#x000a0;al. synthesised BTA derivatives which incorporate piperazine moieties and evaluated their cytotoxicity against different cancer cell lines such as HUH-7 (Heptacellular), MCF-7 (Breast) and HCT-116 (Colorectal). GI<sub>50</sub> values of these derivatives indicated that all compounds exhibited good potential against the aforementioned cell lines but the pyridine containing derivative <bold>18</bold> (<xref ref-type="fig" rid="F0011">Figure 11</xref>) had a remarkable cytotoxic activity with GI<sub>50</sub> value 7.9&#x02009;&#x000b5;M, 9.2&#x02009;&#x000b5;M and 3.1&#x02009;&#x000b5;M for HCT-116, MCF-7 and HUH-7 respectively. Apoptosis caused by this derivative during cell cycle arrest at subG1 phase was confirmed by Hoechst staining and fluorescence activated cell sorting analysis<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>.</p><fig id="F0011" orientation="portrait" position="float"><label>Figure 11.</label><caption><p>Pyridine conataining piperazine benzothiazole derivative <bold>18</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0011_B"/></fig></sec><sec id="S0002-S2004" disp-level="2"><label>2.4.</label><title>Oxadiazole based benzothiazole derivatives as anticancer agents</title><p>Akhtar et&#x000a0;al. synthesised BTA and 1,3,4-oxadiazole-2-thione derivatives and determined their antitumor potential in <italic>in-vitro</italic> against different tumour cell lines. BTA derivatives <bold>19</bold> (N-(benzo[d]thiazol-2-yl)-2&#x02013;(5-(1&#x02013;(2-chlorophenoxy)propyl)-1,3,4-oxadiazol-2-ylthio)acetamide) and <bold>20</bold> (N-(benzo[d]thiazol-2-yl)-2&#x02013;(5-(1&#x02013;(3,4-dichlorophenoxy)ethyl)-1,3,4-oxadiazol-2-ylthio) acetamide) exhibited remarkable activities against CCRF-CEM (leukaemia) cell lines. The CC<sub>50</sub> values of compounds <bold>19</bold> and <bold>20</bold> (CC<sub>50</sub> = 12&#x02009;<inline-formula id="ilm0002"><alternatives><inline-graphic xlink:href="IENZ_A_1698036_ILM0002.jpg"/><mml:math id="d2e754"><mml:mo>&#x000b1;</mml:mo></mml:math></alternatives></inline-formula>&#x02009;2&#x02009;&#x000b5;M and 8&#x02009;<inline-formula id="ilm0003"><alternatives><inline-graphic xlink:href="IENZ_A_1698036_ILM0003.jpg"/><mml:math id="d2e760"><mml:mo>&#x000b1;</mml:mo></mml:math></alternatives></inline-formula>&#x02009;1&#x02009;&#x000b5;M respectively) were comparable to the standard drug Doxorubicin. The replacement of the chloro moiety with bromo in the hybrid structures of <bold>19</bold> and <bold>20</bold> decreased their anti-tumour potential (<xref ref-type="fig" rid="F0012">Figure 12</xref>)<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>.</p><fig id="F0012" orientation="portrait" position="float"><label>Figure 12.</label><caption><p>Oxadiazole based acetamide benzothiazole derivatives <bold>19</bold> and <bold>20</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0012_B"/></fig></sec><sec id="S0002-S2005" disp-level="2"><label>2.5.</label><title>Morpholine-thiourea based benzothiazole derivatives as anticancer agents</title><p>Saeed et&#x000a0;al. reported the synthesis of benzothiazole moiety based thiourea derivatives. These novel derivatives were tested for anticancer potential against cancer cell lines MCF-7 and HeLa cells. The MTT assay (colorimetric assessment of cell metabolic activity) indicated that the thiophene based acetamide benzothiazole derivatives <bold>21</bold> (<xref ref-type="fig" rid="F0013">Figure 13</xref>), morpholine based thiourea aminobenzothiazole derivative <bold>22</bold> (<xref ref-type="fig" rid="F0013">Figure 13</xref>) and morpholine based thiourea bromobenzothiazole <bold>23</bold> (<xref ref-type="fig" rid="F0013">Figures 13</xref>) were potent anticancer agents having IC<sub>50</sub> values of 24.15, 26.43 and 18.10&#x02009;&#x000b5;M against MCF-7 cell line, and of 46.46, 45.29 and 38.85&#x02009;&#x000b5;M against HeLa cells lines respectively<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>.</p><fig id="F0013" orientation="portrait" position="float"><label>Figure 13.</label><caption><p>Morpholine based thiourea bromobenzothiazoles <bold>22&#x02013;24</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0013_B"/></fig><p>Lei et&#x000a0;al. obtained the morpholine based acetamide benzothiazole derivative <bold>24</bold> (<xref ref-type="fig" rid="F0014">Figure 14</xref>) by the treatment of morpholine with 2-chloroacetyl chloride and studied its anticancer activity against HCC (human hepatocellular carcinoma) cell lines HepG2 and Bel7402, reporting IC<sub>50</sub> value for HepG2 and Bel7402 in the millimolar range<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>.<sup>.</sup></p><fig id="F0014" orientation="portrait" position="float"><label>Figure 14.</label><caption><p>Morpholine based acetamide benzothiazole <bold>24</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0014_B"/></fig></sec><sec id="S0002-S2006" disp-level="2"><label>2.6.</label><title>Thiophene based benzothiazole derivatives as anticancer agents</title><p>Racane et&#x000a0;al. obtained the furyl and thienyl based diamidino substituted derivatives of phenyl-BTA and screened them for antiproliferative activities against different tumour cell line <italic>in&#x000a0;vitro</italic>. Derivative <bold>25</bold> (diamidino-substituted thiophene based BTA, <xref ref-type="fig" rid="F0015">Figure 15</xref>) and <bold>26</bold> (imidazolinyl-substituted thiophene based BTA; <xref ref-type="fig" rid="F0015">Figure 15</xref>) exhibited low cytotoxic effects on normal human fibroblasts and strong antiproliferative effects on MiaPaCa-2 and MCF-7 cancer cell lines. The experimental data indicated that the benzothiazole derivatives having thiophene and imidazole substitions possessed interesting antiproliferative activities<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref>.</p><fig id="F0015" orientation="portrait" position="float"><label>Figure 15.</label><caption><p>Imidazolinyl-substituted thiophene-based benzohiazoles <bold>25</bold> and <bold>26</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0015_B"/></fig></sec><sec id="S0002-S2007" disp-level="2"><label>2.7.</label><title>Thiadiazole based benzothiazole derivatives as anticancer agents</title><p>Sekar et&#x000a0;al. reported the synthesis and anticancer activities of six noval BTA derivatives. All derivatives exhibited anticancer activities from a high to a moderate activity level with the substituted thiadiazole flourobenzothiazole <bold>27</bold> (<xref ref-type="fig" rid="F0016">Figure 16</xref>) and methoxybenzothiazole <bold>28</bold> (<xref ref-type="fig" rid="F0016">Figure 16</xref>) showing the best anti-cancer potential due to the presence of highly electronative and electron denoting pharmacophores (e.g. fluorine and methoxy moieties)<xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref>.</p><fig id="F0016" orientation="portrait" position="float"><label>Figure 16.</label><caption><p>Substituted thiadiazole based BTAs <bold>27</bold> and <bold>28</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0016_B"/></fig></sec><sec id="S0002-S2008" disp-level="2"><label>2.8.</label><title>Substituted pyridine based benzothiazole derivatives as anticancer agents</title><p>Shi et&#x000a0;al. synthesised 20 BTA-2-thiol derivatives and investigated their anti-tumour potential against different cell lines such as SW480 (colon adenocarcinoma), HeLa, A549, HCT-116, HepG2 and SKRB-3 breast cancer cell line. The substituted bromopyridine acetamide benzothiazole derivative <bold>29</bold> (<xref ref-type="fig" rid="F0017">Figure 17</xref>) showed potent antitumor activity against SKRB-3, SW620, A549 and HepG2 cell lines with IC<sub>50</sub> values of 1.2&#x02009;nM, 4.3&#x02009;nM, 44&#x02009;nM and 48&#x02009;nM, respectively. Apoptosis was the mechanism of cell death and was concentration dependent in HepaG2 cells. These results indicated that BTA-2-thiols exhibit broad spectrum anti-cancer activities which are worth to be further investigated<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>.</p><fig id="F0017" orientation="portrait" position="float"><label>Figure 17.</label><caption><p>Substituted bromopyridine based acetamide benzothiazole derivative <bold>29</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0017_B"/></fig><p>Xuejiao et&#x000a0;al. reported the synthesis of a substituted pyridine based acetamide BTA derivative <bold>30</bold> (<xref ref-type="fig" rid="F0018">Figure 18</xref>) and screened its anti-cancer activity both <italic>in&#x000a0;vitro</italic> and <italic>in</italic> v<italic>ivo.</italic> Derivative <bold>30</bold> demonstrated anti-proliferative activities against a wide spectrum of human cell lines and induced the mitochondrial apoptotic pathway in HepaG2 cell lines. The BTA scaffold <bold>30</bold> proved to be a promising candidate for cancer chemotherapy<xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref>.</p><fig id="F0018" orientation="portrait" position="float"><label>Figure 18.</label><caption><p>Substituted pyridine based acetamide benzothiazole <bold>30</bold> and pyridine containing pyrimidine benzothiazole <bold>31</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0018_B"/></fig><p>Kamal et&#x000a0;al. reported the synthesis of novel phenyl pyridopyrimidinones based BTA derivatives which were examined against four different cancer cell lines such as ME-180, DU-145, MCF-7 and B-16. The pyridine containing pyrimidine benzothiazole <bold>31</bold> (<xref ref-type="fig" rid="F0018">Figure 18</xref>) exhibited interesting cytotoxicity with IC<sub>50</sub> value of 4.01&#x02009;&#x000b5;M against ME-180 (human cervical cancer cell line)<xref rid="CIT0038" ref-type="bibr"><sup>38</sup></xref>.</p></sec><sec id="S0002-S2009" disp-level="2"><label>2.9.</label><title>Pyrazole based benzothiazole derivatives as anticancer agents</title><p>Gabr et&#x000a0;al. reported the synthesis and evaluation of novel BTA scaffolds against 60 tumour cell lines at a single dose of 10&#x02009;&#x000b5;M. The best derivatives were <bold>32</bold> (<xref ref-type="fig" rid="F0019">Figure 19</xref>) and <bold>33</bold> (<xref ref-type="fig" rid="F0019">Figure 19</xref>), which were further screened at 5 doses. These derivatives demonstrated interesting anticancer activity at micro molar and sub micro molar concentrations, against all sixty tumour cell lines with GI<sub>50</sub> in the low micro molar or submicromolar range. The SAR study revealed that introduction of the pyrazole moiety significantly enhanced the antitumor activity of both derivatives. Furthermore the presence of 2-hydroxy ester and 3-oxopyrazole within the pyrimidine moiety increased the anti-tumour activities of both derivatives. The simple BTA scafolds having pyrazole functionalities were more potent against different cell lines as compared to derivatives having the pyrazole ring within a pyrimidine moiety<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>.</p><fig id="F0019" orientation="portrait" position="float"><label>Figure 19.</label><caption><p>Pyrazole based benzothiazoles <bold>32</bold> and <bold>33</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0019_B"/></fig></sec><sec id="S0002-S2010" disp-level="2"><label>2.10.</label><title>Pyrimidine based benzothiazole derivatives as anticancer agents</title><p>Kambhare et&#x000a0;al. synthesised the isoxazole pyrimidine based BTAs and evaluated them for anticancer activity by the MTT assay against different cell lines such as A549, Colo205, MCF-7 and U937 cell lines, in comparison with the standard drug etoposide. The pyridine containing pyrimidine derivative <bold>34</bold> (<xref ref-type="fig" rid="F0020">Figure 20</xref>) demonstrated good anti-cancer potential with IC<sub>50</sub> value 5.04&#x02009;&#x000b5;M against colo205, 13.9&#x02009;&#x000b5;M against U937, 30.67&#x02009;&#x000b5;M against MCF-7 and 30.45&#x02009;&#x000b5;M against A549 cell lines when compared with standard drug etoposide. The scaffold <bold>34</bold> activated p53 or TP53 (tumour protein) pathways, which regulate the equilibrium between apoptosis and cell proliferation. The SAR explained that the maximum cytotoxicity of derivative <bold>34</bold> against colon cancer cell line was due to the presence of methoxy group (&#x02013;OCH<sub>3</sub>) in the phenyl<xref rid="CIT0040" ref-type="bibr"><sup>40</sup></xref>.</p><fig id="F0020" orientation="portrait" position="float"><label>Figure 20.</label><caption><p>Structure of pyrimidine based isoxazole derivative <bold>34</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0020_B"/></fig><p>Waghmare et&#x000a0;al. reported the synthesis of substituted pyrimidine containing benzothiazole derivative <bold>35</bold> (<xref ref-type="fig" rid="F0021">Figure 21</xref>) by refluxing BTAs with bis-methylthio methylene malononitrile, and tested their anticancer activity against 18 different cell lines. The scaffold <bold>35</bold> possessed excellent anticancer activity with a good percentage of growth inhibition against lung cancer, breast cancer and renal cancer cell lines. The good anticancer activity of derivative <bold>35</bold> is due to the presence of two methyl and one SCH<sub>3</sub> groups in its structure<xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref>.</p><fig id="F0021" orientation="portrait" position="float"><label>Figure 21.</label><caption><p>Pyrimidine based benzothiazole derivative <bold>35</bold> and <bold>36</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0021_B"/></fig><p>Caleta et&#x000a0;al. synthesised cyano and amidinobenzothiazole substituted anilins which were treated with 2-bromo-6-cyanobenzothiazole under specific reaction conditions to afford compounds which have been studied for their anticancer activity against 6 cancer cell lines such as laryngeal carcinoma (Hep-2), breast carcinoma (MCF-7), cervical carcinoma (HeLa), pancreatic carcinoma (MiaPaCa-2), colon carcinoma (SW 620), lung carcinoma (H 460), and diploid fibroblasts (WI 38). Among them, the pyrimidine based carbonitrile benzothiazole derivative <bold>36</bold> (<xref ref-type="fig" rid="F0021">Figure 21</xref>) showed potent activity against all cancer cell lines used in the study<xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref>.</p></sec><sec id="S0002-S2011" disp-level="2"><label>2.11.</label><title>Piperidine based benzothiazole derivatives as anticancer agents</title><p>Osmaniye et&#x000a0;al. prepared BTA acylhydrazone using 4-fluorobenzaldehyde refluxed with substituted amines, to afford the desired derivatives and studied their anticancer activities against rat brain glioma (carcinogenic C6) cell line, human lung adenocarcinoma epithelial (A549) cell line, human breast adenocarcinoma (MCF-7) cell line, human colorectal adenocarcinoma (HT-29) cell line and mouse embryo fibroblast (NIH3T3) cell line. The piperidine based acetohydrazide derivative <bold>37</bold> (<xref ref-type="fig" rid="F0022">Figure 22</xref>) showed modest activity having IC<sub>50</sub> value 1&#x02009;&#x0003c;&#x02009;mM, 0.03&#x02009;mM, 0.10&#x02009;mM, 0.30&#x02009;mM and 1&#x0003c; mM for A549, HT-29, MCF-7, C6, and NIH3T3 cell lines respectively against reference drug cisplatin<xref rid="CIT0043" ref-type="bibr"><sup>43</sup></xref>.</p><fig id="F0022" orientation="portrait" position="float"><label>Figure 22.</label><caption><p>Piperidine based acetohydrazide benzothiazole <bold>37</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0022_B"/></fig></sec><sec id="S0002-S2012" disp-level="2"><label>2.12.</label><title>Secondary sulphonamide benzothiazole derivatives as anticancer agents</title><p>Lad et&#x000a0;al. reported the synthesis of a series of methylsulfonyl benzothiazoles, obtained from 5-ethoxybenzothiazol-2-amine which were tested their anticancer activities. Among these derivatives, the nitrophenyl sulphonamide based methylsulfonyl benzothiazole <bold>38</bold> (<xref ref-type="fig" rid="F0023">Figure 23</xref>) and <italic>ter</italic>-butyl sulphonamide based methylsulfonyl benzothiazole <bold>39</bold> (<xref ref-type="fig" rid="F0023">Figure 23</xref>) exhibited the best anticancer activities against HeLa cell line with the IG<sub>50</sub> value of 0.22&#x02009;&#x000b5;M and 0.6&#x02009;&#x000b5;M respectively<xref rid="CIT0044" ref-type="bibr"><sup>44</sup></xref>.</p><fig id="F0023" orientation="portrait" position="float"><label>Figure 23.</label><caption><p>Sulphonamide based methylsulfonyl benzothiazoles <bold>38</bold> and <bold>39</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0023_B"/></fig><p>Sadhasivam et&#x000a0;al. reported the synthesis of 2, 6-disubstituted-BTA by reaction of 2-amino-6-nitrobenzothiazole and acetic anhydride and studied their anticancer activity against three cancer cell lines MCF-7, HeLa and MG63 (human osteosarcoma) The sulphonamide scaffold based BTA <bold>40</bold> (<xref ref-type="fig" rid="F0024">Figure 24</xref>) exhibited modest anti-cancer activity with IC<sub>50</sub> of 34.5&#x02009;&#x000b5;M for MCF-7, 44.15&#x02009;&#x000b5;M for HeLa and 36.1&#x02009;&#x000b5;M for the MG63<xref rid="CIT0045" ref-type="bibr"><sup>45</sup></xref>.</p><fig id="F0024" orientation="portrait" position="float"><label>Figure 24.</label><caption><p>Secondary sulphonamide based acetamide benzothiazole <bold>40</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0024_B"/></fig></sec><sec id="S0002-S2013" disp-level="2"><label>2.13.</label><title>Benzamide based benzothiazole derivatives as anticancer agents</title><p>Wang et&#x000a0;al. synthesised and evaluated 24 benzothiazole-2-thiol derivatives for antiproliferative activities against different human cancer cell lines such as A549, HCT-116, SW620, SW480, MDA-MB-468, SKRB-3, HeLa, SKOV-3, PC-3, BxPC-3, A431 and A375. Some derivatives exhibited better anticancer activities as compared to the standard drug cisplatin. The substituted methoxybenzamide benzothiazole <bold>41</bold> and the substituted chloromethylbenzamide benzothiazole <bold>42</bold> (<xref ref-type="fig" rid="F0025">Figure 25</xref>) showed good anti-tumour potential <italic>in&#x000a0;vitro</italic>, with IC<sub>50</sub> values ranging from 1.1&#x02009;&#x000b5;M to 8.8&#x02009;&#x000b5;M. The introduction of chloromethyl and methoxy functionalities in compounds <bold>41</bold> and <bold>42</bold> increased their anticancer activity compared to other synthesised analogs<xref rid="CIT0046" ref-type="bibr"><sup>46</sup></xref>.</p><fig id="F0025" orientation="portrait" position="float"><label>Figure 25.</label><caption><p>Substituted methoxybenzamide based benzothiazole derivative <bold>41</bold> and chloromethylbenzamide based benzothiazole <bold>42</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0025_B"/></fig><p>Bolelli et&#x000a0;al. synthesised 2-substituted benzothiazoles by the reaction of carboxylic acid with thionyl chloride which afforded acyl chlorides, further treated with substituted benzothiazole to give 2-substituted benzothiazoles, which were studied for their inhibitory activities against human glutathione transferases (hGSTP1-1). The benzamide benzothiazole derivative <bold>43</bold> and benzamide methylbenzothiazole <bold>44</bold> (<xref ref-type="fig" rid="F0026">Figure 26</xref>) showed potent hGSTP1-1 inhibitory activities, useful in cancer chemotherapy. The SAR studies pinpointed that both these scaffold showed effective inhibition due to the presence of <italic>para</italic>-substitutions on the phenyl ring of the benzamide group<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref>.</p><fig id="F0026" orientation="portrait" position="float"><label>Figure 26.</label><caption><p>Benzamide containing benzothiazoles <bold>43</bold> and <bold>44</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0026_B"/></fig><p>Corbo et&#x000a0;al. reported 19 derivatives of benzamide based BTAs by the reaction of substituted aniline, potassium thiocyante and bromine, which afforded substituted compounds which were tested for anti-proliferative activity against MCF-7 and HepG2 cell lines. The substituted diflourobenzamide containing benzothiazole <bold>45</bold> (<xref ref-type="fig" rid="F0027">Figure 27</xref>) proved to be a potent anti-proliferative compound with the percentual inhibition of 64&#x02009;&#x000b1;&#x02009;2 &#x000b5;M for MCF-7 cell line and of 64&#x02009;&#x000b1;&#x02009;6 &#x000b5;M for HepG2 cell line<xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref>.</p><fig id="F0027" orientation="portrait" position="float"><label>Figure 27.</label><caption><p>Substituted difluorobenzamide BTA derivative <bold>45</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0027_B"/></fig></sec><sec id="S0002-S2014" disp-level="2"><label>2.14.</label><title>Quinolone based benzothiazole derivatives</title><p>Abdelgawad et&#x000a0;al. synthesised quinolone based benzothiazole derivatives by the treatment of substituted benzothiazoles with aromatic aldehydes. The nitrobenzylidene containing quinolone derivative <bold>46</bold> (<xref ref-type="fig" rid="F0028">Figure 28</xref>) and the hydroxybenzylidine containing derivative <bold>47</bold> (<xref ref-type="fig" rid="F0028">Figure 28</xref>) showed antitumor activities against the MCF-7 cell line, having IC<sub>50</sub> values of 0.058&#x02009;&#x000b5;M and 0.052&#x02009;&#x000b5;M, respectively<xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref>.</p><fig id="F0028" orientation="portrait" position="float"><label>Figure 28.</label><caption><p>Hydroxybenzylidine containing quinolone benzothiazole derivative <bold>46</bold> and <bold>the</bold> nitrobenzylidene quinolone derivative <bold>47</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0028_B"/></fig><p>Sarkar et&#x000a0;al. prepared benzothiazolyl quinoline derivatives by treatment of 2-aminobenzothiol with 2-hydroxy-benzaldehyde and studied their activities for the A1, A2A, A2B and A3 adenosine receptors. The A3 receptor is overexpressed in different cancer cell lines. The quinolone based derivative <bold>48</bold> (<xref ref-type="fig" rid="F0029">Figure 29</xref>) showed the maximum potency for the hA3 adenosine receptor<xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>.</p><fig id="F0029" orientation="portrait" position="float"><label>Figure 29.</label><caption><p>Quinolone based benzothiazole derivative <bold>48</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0029_B"/></fig></sec><sec id="S0002-S2015" disp-level="2"><label>2.15.</label><title>Miscellaneous benzothiazole derivatives as anticancer agents</title><p>Tay et&#x000a0;al. synthesised and evaluated <italic>N</italic>-[4-(benzothiazole-2yl) phenyl]-2-aryloxyacetamide derivatives for cytotoxicity and anticancer activity against sixty human cancer cell lines derived from 9 neoplastic diseases, among which L (leukaemia), M (melanoma), RC (renal cancer) NSCLC (non-small cell lung cancer) CC (colon cancer), OC (ovar ian cancer), BC (breast cancer), CNSC (central nervous system cancer) and PC (prostate cancer). Derivatives <bold>49</bold> (<italic>N</italic>-(4-(benzo[d]thiazol-2-yl)-3-methoxyphenyl)-3&#x02013;(4-chlorophenyl)propanamide) and <bold>50</bold> (<italic>N</italic>-(4-(benzo[d]thiazol-2-yl)-2-chlorophenyl)-2&#x02013;(4-chlorophenylthio)acetamide) (<xref ref-type="fig" rid="F0030">Figure 30</xref>) exhibited interesting anti-cancer activities. The SAR studies investigated that anticancer activities of these compounds were due to the substitutions (methoxy and chloro groups) present in their molecules<xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref>.</p><fig id="F0030" orientation="portrait" position="float"><label>Figure 30.</label><caption><p>Substituted propanamide/acetamide based benzothiazoles <bold>49</bold> and <bold>50</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0030_B"/></fig><p>Noolvi et&#x000a0;al. reported the synthesis of chloro substituted benzothiazole amines in order to produce isothiocyanates and thioureases. These BTA derivatives were tested for their anticancer activities. The dichlorophenyl containing chlorobenzothiazole <bold>51</bold> (<xref ref-type="fig" rid="F0031">Figure 31</xref>) showed good anticancer activity against 9 different cancer cell lines having GI<sub>50</sub> values in the range of 1.60&#x02009;&#x000b5;M&#x02013;71.8&#x02009;nM. The derivative <bold>51</bold> exhibited GI<sub>50</sub> = 7.18&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;8&#x02009;</sup>M against non-small cell lung cancer (HOP-92). The SAR studies showed that the highest activity of compound <bold>51</bold> was due to the presence of three chlorine atoms in the compound as compared to other derivatives<xref rid="CIT0052" ref-type="bibr"><sup>52</sup></xref>.</p><fig id="F0031" orientation="portrait" position="float"><label>Figure 31.</label><caption><p>Dichlorophenyl-chlorobenzothiazole derivative <bold>51</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0031_B"/></fig><p>Havrylyuk et&#x000a0;al. screened novel 4-thiazolidinone benzothiazole derivatives against ovarian, renal, prostate, leukaemia, melanoma, lung, colon, CNS and breast cancer cell lines. The thioxothiazolidine acetamide benzothiazole <bold>52</bold> (<xref ref-type="fig" rid="F0032">Figure 32</xref>) showed the most promising anti-cancer activity. The SAR studies pinpointed that the introduction of 4-chloro-phenoxy-<italic>N</italic>-(4-methoxyphenyl)-acetamide substitutions on position 5 of the 4-thiazolidinones ring enhanced the anti-cancer potential<xref rid="CIT0053" ref-type="bibr"><sup>53</sup></xref>.</p><fig id="F0032" orientation="portrait" position="float"><label>Figure 32.</label><caption><p>Substituted thioxothiazolidine acetamide benzothiazole derivative <bold>52</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0032_B"/></fig><p>Prabhu et&#x000a0;al. synthesised and studied the anticancer activities of oxothiazolidine based BTA derivatives. The substituted chlorophenyl oxothiazolidine based benzothiazole <bold>53</bold> (<xref ref-type="fig" rid="F0033">Figure 33</xref>) showed the most effective anticancer activity against HeLa cell line, inducing 96.8% inhibition and IC<sub>50</sub> value of 9.76&#x02009;&#x000b5;M, when compared with the reference drug cisplatin<xref rid="CIT0054" ref-type="bibr"><sup>54</sup></xref>.</p><fig id="F0033" orientation="portrait" position="float"><label>Figure 33.</label><caption><p>Oxothiazolidine based benzothiazole derivative <bold>53</bold> and thiazolidine benzothiazole derivative <bold>54</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0033_B"/></fig><p>Abdelgawad et&#x000a0;al. synthesised thiazolidinone containing benzoxazole derivatives by the treatment of aminobenzoic acid with substituted aniline that further reacted in different steps under specific conditions to afford final product and studied their anticancer activities against breast cancer (MCF7) and liver cancer (HEPG2) cell lines. Among all these derivatives, nitrobenzylidene containing thiazolidine derivative <bold>54</bold> (<xref ref-type="fig" rid="F0033">Figure 33</xref>) exhibited some anticancer activity, with an IC<sub>50</sub> value of 36&#x02009;nM and 48&#x02009;nM against MCF7 and HEPG2, respectively<xref rid="CIT0055" ref-type="bibr"><sup>55</sup></xref>.</p><p>Ma et&#x000a0;al. reported indole based BTA derivatives and studied their anticancer activities. Among all these derivatives, the chlorobenzyl indole semicarbazide benzothiazole <bold>55</bold> (<xref ref-type="fig" rid="F0034">Figure 34</xref>) exhibited anticancer activity against four cancer cell lines such as HT-29, H460, A549 and MDA-MB-231. Derivative <bold>55</bold> showed IC<sub>50</sub> values of 0.024&#x02009;&#x000b5;M for HT-29, 0.29&#x02009;&#x000b5;M for H460, 0.84&#x02009;&#x000b5;M for A549 and 0.88&#x02009;&#x000b5;M for MDA-MB-231, respectively<xref rid="CIT0056" ref-type="bibr"><sup>56</sup></xref>.</p><fig id="F0034" orientation="portrait" position="float"><label>Figure 34.</label><caption><p>Chlorobenzyl indole semicarbazide BTA derivative <bold>55</bold> and urea BTA derivative <bold>56</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0034_B"/></fig><p>Xie et&#x000a0;al. prepared substituted BTA derivatives and studied their anticancer activities. Among all derivatives, the urea benzothiazole <bold>56</bold> (<xref ref-type="fig" rid="F0034">Figure 34</xref>) exhibited interesting antitumor activity against 60 cancer cell lines. The average GI<sub>50</sub> value for derivative <bold>56</bold> was 0.38&#x02009;&#x000b5;M<xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref>.</p><p>Uremis et&#x000a0;al. synthesised BTA derivatives using substituted aldehyde with bicyclo[3.2.0]hept-2-en-6-one. The nitro-styryl containing benzothiazole derivative <bold>57</bold> and the fluorostyryl benzothiazole derivative <bold>58</bold> (<xref ref-type="fig" rid="F0035">Figure 35</xref>) were reported for their anticancer activity against pancreatic cancer cells having IC<sub>50</sub> values of 27&#x02009;&#x000b1;&#x02009;0.24&#x02009;&#x000b5;M for <bold>57</bold> and of 35&#x02009;&#x000b1;&#x02009;0.51&#x02009;&#x000b5;M for derivative <bold>58</bold><xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref>.</p><fig id="F0035" orientation="portrait" position="float"><label>Figure 35.</label><caption><p>Nitrostyryl containing BTA derivative <bold>57</bold> and fluorostyryl BTA derivative <bold>58</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0035_B"/></fig><p>Cindric et&#x000a0;al. obtained carboxamide containing benzothiazole by the condensation of substituted thiophenes and substituted amino-BTAs to prepare the desired product and studied their anticancer activity against MCF-7 cell line. The benzothiophene based carboxamide chloroaminobenzothiazole <bold>59</bold> (<xref ref-type="fig" rid="F0036">Figure 36</xref>) exhibited potent anticancer activity with an IC<sub>50</sub> of 40&#x02009;nM<xref rid="CIT0059" ref-type="bibr"><sup>59</sup></xref>.</p><fig id="F0036" orientation="portrait" position="float"><label>Figure 36.</label><caption><p>Benzothiophene carboxamide chloroaminobenzothiazole derivative <bold>59</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0036_B"/></fig><p>Nikolova et&#x000a0;al. obtained Ru(III) complexes containing benzothiazole derivatives and tested their anticancer activity against K-562 and KE-37 (human leukemic) cell lines. Among all these derivatives, the Ru(III) containing methylbenzothiazole <bold>60</bold> (<xref ref-type="fig" rid="F0037">Figure 37</xref>) exhibited the highest cytotoxic activity against K-562 and KE-37, having IC<sub>50</sub> values of 7.74&#x02009;&#x000b1;&#x02009;2.50 for KE-37 and of 16.21&#x02009;&#x000b1;&#x02009;2.33 for K-562 when compared with the standard drug cisplatin<xref rid="CIT0060" ref-type="bibr"><sup>60</sup></xref>.</p><fig id="F0037" orientation="portrait" position="float"><label>Figure 37.</label><caption><p>Ru(III) containing methylbenzothiazole derivative <bold>60</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0037_B"/></fig><p>Yurttas et&#x000a0;al. obtained benzothiazole derivatives by acetylation of substituted benzothiazole with chloroacetyl chloride that was further treated in series of reactions to obtain specific derivatives which were tested for their anticancer activities against lung carcinoma (A549) cell line. Derivatives <bold>61</bold> and derivative <bold>62</bold> (<xref ref-type="fig" rid="F0038">Figure 38</xref>) exhibited good anticancer activities against A549 with IC<sub>50</sub> values of 10.67&#x02009;&#x000b1;&#x02009;2.02 &#x000b5;g/mL and 9.0&#x02009;&#x000b1;&#x02009;1.0 &#x000b5;g/mL respectively as compared to the reference compound cisplatin<xref rid="CIT0061" ref-type="bibr"><sup>61</sup></xref>.</p><fig id="F0038" orientation="portrait" position="float"><label>Figure 38.</label><caption><p>Benzimidazole based acetamide methoxybenzothiazole derivative <bold>61</bold> and acetamide ethoxybenzothiazole derivative <bold>62</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0038_B"/></fig><p>Oanh et&#x000a0;al. reported the synthesis of hydroxamic acids containing benzothiazole by the reaction of 2-aminobenzothiazole with adipic acid to produce esters that were converted into the desired BTA hydroxamates, and tested for their anticancer activities against five different cell lines such MCF-7, AsPC-1, SW620, PC3 and NCI-H460. Among the synthesised derivatives, hydroxamic acids <bold>63</bold> and <bold>64</bold> (<xref ref-type="fig" rid="F0039">Figure 39</xref>) exhibited good anticancer activities, with the average IC<sub>50</sub> value of 0.81&#x02009;&#x000b5;g/mL and 1.28&#x02009;&#x000b5;g/mL respectively<xref rid="CIT0062" ref-type="bibr"><sup>62</sup></xref>.</p><fig id="F0039" orientation="portrait" position="float"><label>Figure 39.</label><caption><p>Hydroxamic acid containing methyl/methoxy benzothiazole scaffolds <bold>63</bold> and <bold>64</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0039_B"/></fig><p>Rodrigues et&#x000a0;al. synthesised carbohydrazide containing BTA derivatives and studied their antitumor activities against human prostate cancer cell lines. <italic>N</italic>&#x02032;-formyl-2&#x02013;(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide <bold>65</bold> (<xref ref-type="fig" rid="F0040">Figure 40</xref>) exhibited potent anticancer activity against PC-3 and LNCaP having IC<sub>50</sub> values 19.9&#x02009;&#x000b1;&#x02009;1.17 and 11.2&#x02009;&#x000b1;&#x02009;0.79&#x02009;&#x000b5;g/m respectively<xref rid="CIT0063" ref-type="bibr"><sup>63</sup></xref>.</p><fig id="F0040" orientation="portrait" position="float"><label>Figure 40.</label><caption><p>Derivative <bold>65&#x02013;67</bold> discussed in the article.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0040_B"/></fig><p>Rao et&#x000a0;al. reportyed DNA-intercalating naphthalimide-benzothiazole derivatives and evaluated their cytotoxicities against three different cancer cell lines such as HT29, A549 and MCF-7. Among all tested derivatives, the naphthalimide derivative <bold>66</bold> (<xref ref-type="fig" rid="F0040">Figure 40</xref>) possessed good antitumor activity against HT-29, A549 and MCF-7 cell lines having IC<sub>50</sub> values of 3.72&#x02009;&#x000b1;&#x02009;0.3&#x02009;&#x000b5;M, 4.074&#x02009;&#x000b1;&#x02009;0.3&#x02009;&#x000b5;M and 07.91&#x02009;&#x000b1;&#x02009;0.4&#x02009;&#x000b5;M respectively. The naphthalimide <bold>67</bold> (<xref ref-type="fig" rid="F0040">Figure 40</xref>) showed antitumor activity with IC<sub>50</sub> values of 03.47&#x02009;&#x000b1;&#x02009;0.2&#x02009;&#x000b5;M for HT-29, 03.89&#x02009;&#x000b1;&#x02009;0.3&#x02009;&#x000b5;M for A549 and 05.08&#x02009;&#x000b1;&#x02009;0.3&#x02009;&#x000b5;M for MCF-7 cell lines<xref rid="CIT0064" ref-type="bibr"><sup>64</sup></xref>.</p><p>Rao et&#x000a0;al. reported the synthesis of 2-arylaminobenzothiazole-arylpropeonones and studied their cytotoxic activities against different human cancer cell lines. Among all synthesised derivatives, substituted phenylamino based methoxybenzothiazole <bold>68</bold> (<xref ref-type="fig" rid="F0041">Figure 41</xref>) and substituted phenylamino based methoxy methylbenzothiazole <bold>69</bold> (<xref ref-type="fig" rid="F0041">Figure 41</xref>) showed potent cytotoxic activity against HeLa cell lines possessing IC<sub>50</sub> values of 0.5&#x02009;&#x000b1;&#x02009;0.02 and 0.6&#x02009;&#x000b1;&#x02009;0.29&#x02009;&#x000b5;M<xref rid="CIT0065" ref-type="bibr"><sup>65</sup></xref>.</p><fig id="F0041" orientation="portrait" position="float"><label>Figure 41.</label><caption><p>Substituted phenylamino based methoxy benzothiazoles <bold>68</bold> and <bold>69</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0041_B"/></fig><p>Osmaniye et&#x000a0;al. synthesised benzothiazole-thiazolidine derivatives and studied their anticancer activities against C6 and healthy NIH3T3 cell lines. Among the synthesised derivatives, substituted phenylthizolidene based benzothiazole <bold>70</bold> and substituted nitrophenylthizolidene benzothiazole <bold>71</bold> (<xref ref-type="fig" rid="F0042">Figure 42</xref>) exhibited some cytotoxic activities against C6 cell line showing IC<sub>50</sub> value 0.03&#x02009;mM. The SAR studies showed that the presence of a phenyl group on the thiazolidine part of the structure increased the selectivity while substitution with an electron withdrawing or donating groups decreased the selectivity<xref rid="CIT0066" ref-type="bibr"><sup>66</sup></xref>.</p><fig id="F0042" orientation="portrait" position="float"><label>Figure 42.</label><caption><p>Substituted phenylthizolidene based benzothiazole derivative <bold>70</bold> and <bold>71</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0042_B"/></fig><sec id="S0002-S2015-S3001" disp-level="3"><title>Benzothiazole derivatives with carbonic anhydrase inhibitory and antitumor action</title><p>Carbonic anhydrases (CAs, EC 4.2.1.1) are zinc enzymes which catalyse the reversible interconversion between CO<sub>2</sub> and bicarbonate<xref rid="CIT0067" ref-type="bibr"><sup>67&#x02013;71</sup></xref>. CO<sub>2</sub> is efficiently hydrated through a zinc hydroxide intermediate from the enzyme active site with generation of the weak base bicarbonate and the strong acid H<sup>+</sup>. As a consequence, CAs are involved in pH regulation, electrolyte secretion and metabolism, in normal and tumour tissues<xref rid="CIT0070" ref-type="bibr"><sup>70&#x02013;72</sup></xref>. Fifteen &#x003b1;-CA isoforms are present in humans, with at least two of tyhem overexporessed in hypoxic tumours (CA IX and XII)<xref rid="CIT0067" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="CIT0071" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="CIT0072" ref-type="bibr"><sup>72</sup></xref>, as a consequence of the hypoxia inducible factor (HIF-1&#x003b1;) transcription factor cascade activation<xref rid="CIT0067" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="CIT0070" ref-type="bibr"><sup>70</sup></xref>. CAs are efficiently inhibited by a range of compounds, such as the sulphonamides and their isosteres<xref rid="CIT0073" ref-type="bibr"><sup>73&#x02013;76</sup></xref>, and inorganic anions<xref rid="CIT0077" ref-type="bibr"><sup>77</sup></xref>, which constitute the main zinc-binding CA inhibitor (CAI) classes<xref rid="CIT0067" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="CIT0076" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="CIT0077" ref-type="bibr"><sup>77</sup></xref>. Some of the CAIs belonging to the sulphonamide<xref rid="CIT0078" ref-type="bibr"><sup>78</sup></xref>, sulfocoumarin<xref rid="CIT0079" ref-type="bibr"><sup>79</sup></xref>, saccharin<xref rid="CIT0080" ref-type="bibr"><sup>80</sup></xref> or other structurally related chemotypes<xref rid="CIT0081" ref-type="bibr"><sup>81</sup></xref><sup>,</sup><xref rid="CIT0082" ref-type="bibr"><sup>82</sup></xref>, were shown to possess significant antitumor effects, with one such derivative (<bold>SLC-0111</bold>) in Phase I/IIb clinical trials for the management of hypoxic metastatic tumours<xref rid="CIT0078" ref-type="bibr"><sup>78</sup></xref><sup>,</sup><xref rid="CIT0083" ref-type="bibr"><sup>83</sup></xref>. Indeed, by inhibiting the tumour-associated isoforms CA IX and XII, such CAIs interfere with the pH regulation and metabolism of tumours, leading to the inhibition of growth of the primary tumour, metastases and reducing the population of cancer stem cells<xref rid="CIT0078" ref-type="bibr"><sup>78</sup></xref>. As a consequence, many CAIs belonging to various classes are nowadays investigated for their antitumor/antimetastatic effects, including many BTA derivatives (<xref ref-type="fig" rid="F0043">Figure 43</xref>)<xref rid="CIT0084" ref-type="bibr"><sup>84&#x02013;91</sup></xref>.</p><fig id="F0043" orientation="portrait" position="float"><label>Figure 43.</label><caption><p>Benzothiazoles with potent CA IX inhibitory action<xref rid="CIT0084" ref-type="bibr"><sup>84&#x02013;91</sup></xref>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1698036_F0043_B"/></fig><p>.Indeed, using the ethoxzolamide <bold>72</bold>, a CAI in clinical use for decades as lead molecule, a multitude of primary sulphonamides (e.g. compounds <bold>73&#x02013;75</bold>) as well as the secondary siulfonamide 76 were reported to act as highly efficient, frequently low nanomolar inhibitors against the tumour-associated isoforms CA IX and XII<xref rid="CIT0084" ref-type="bibr"><sup>84&#x02013;91</sup></xref>. No <italic>ex vivo</italic> or <italic>in&#x000a0;vivo</italic> studies are available so far with these potent CA IX/XII inhibitors, but compounds belonging to other classes of sulphonamides were proved to possess significant antitumor effects in&#x000a0;vivo when they act as potent inhibitors of these two CA isoforms<xref rid="CIT0078" ref-type="bibr"><sup>78</sup></xref><sup>,</sup><xref rid="CIT0092" ref-type="bibr"><sup>92&#x02013;98</sup></xref>. Thus future studes may address this issue, considering the fact that the BTA scaffold present in these compounds may induce interesting phisico-chemical and pharmacologic properties to the CA IX/XII inhibitors, of which many chemical families are alredy reported<xref rid="CIT0099" ref-type="bibr"><sup>99&#x02013;103</sup></xref>.</p></sec></sec></sec><sec id="S0003" disp-level="1"><label>4.</label><title>Conclusions</title><p>Benzothiazole is a pharmacophore widely used in medicinal chemistry. This review points out to a growing interest in the development of lead or hybrid structures bearing the BTA moiety as antiproliferative and anticancer agents. The present work describes the potential of BTA scaffolds in the management of various types of cancers such as ovarian, prostate, central nervous system, renal, gastric, pancreatic, liver, breast and colon cancers. SAR studies reaveled that the anticancer activity of BTA scaffolds depends upon the nature of substituents present in these molecules, being multifactorial and not always easy to rationalise. The plethora of research on the anticancer profile of BTA derivatives mentioned in this review and their rationalisation based on the drug targets of these derivatives, when this was possible, may be useful for the development of novel such agents.</p></sec></body><back><sec id="S0004" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhtar</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>Z.</given-names></name></person-group>
<article-title>Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities</article-title>. <source>Eur J Med Chem</source>
<year>2017</year>;<volume>5</volume>:<fpage>143</fpage>&#x02013;<lpage>89</lpage>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keri</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Patil</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Patil</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Budagumpi</surname><given-names>S.</given-names></name></person-group>
<article-title>A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry</article-title>. <source>Eur J Med Chem</source>
<year>2015</year>;<volume>89</volume>:<fpage>207</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">25462241</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunawardana</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Koehn</surname><given-names>FE</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>AY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pyridoacridine alkaloids from deep water marine sponges of the family Pachastrellidae: structure revision of dercitin and related compounds and correlation with the Kuanoniamines</article-title>. <source>J Org Chem</source>
<year>1992</year>;<volume>57</volume>:<fpage>1523</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaiswal</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>A.</given-names></name></person-group>
<article-title>The different kinds of reaction involved in synthesis of 2-substituted 2enzothiazole and its derivatives: a review</article-title>. <source>Res J Pharm Biol Chem Sci</source>
<year>2012</year>;<volume>3</volume>:<fpage>631</fpage>&#x02013;<lpage>41</lpage>.</mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fulton</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Benfield</surname><given-names>P.</given-names></name></person-group>
<article-title>Riluzole a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis</article-title>. <source>Drugs</source>
<year>1996</year>;<volume>52</volume>:<fpage>549</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">8891467</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatesh</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pandeya</surname><given-names>NS.</given-names></name></person-group>
<article-title>Synthesis, characterisation and anti-inflammatory activity of some 2-amino benzothiazole derivatives</article-title>. <source>Int J ChemTech Res</source>
<year>2009</year>;<volume>1</volume>:<fpage>1354</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>G</given-names></name></person-group>, et.al. <article-title>Novel benzothiazole derivatives with a broad antifungal spectrum: design, synthesis and structure&#x02013;activity relationships</article-title>. <source>Med Chem Commun</source>
<year>2013</year>;<volume>4</volume>:<fpage>1551</fpage>&#x02013;<lpage>61</lpage>.</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mats</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Shani</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Pasternak</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives</article-title>. <source>J Med Chem</source>
<year>2013</year>;<volume>56</volume>:<fpage>5335</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">23750537</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bele</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Singhvi</surname><given-names>I.</given-names></name></person-group>
<article-title>Synthesis and analgesic activity of some Mannich bases of 6-substituted-2-aminobenzothiazole</article-title>. <source>Res J Pharm and Tech</source>
<year>2008</year>;<volume>1</volume>:<fpage>22</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padalkar</surname><given-names>SV</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>DV</given-names></name>, <name name-style="western"><surname>Phatangare</surname><given-names>RK</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of novel dipodal-benzimidazole, benzoxazole and benzothiazole from cyanuric chloride: structural, photophysical and antimicrobial studies</article-title>. <source>J Saudi Chem Soc</source>
<year>2014</year>;<volume>18</volume>:<fpage>262</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents</article-title>. <source>Eur J Med Chem</source>
<year>2013</year>;<volume>63</volume>:<fpage>702</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">23567960</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delmas</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Avellaneda</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Giorgio</surname><given-names>DC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and antileishmanial activity of (1,3-benzothiazol-2-yl) amino-9-(10H)-acridinone derivatives</article-title>. <source>Eur J Med Chem</source>
<year>2004</year>;<volume>39</volume>:<fpage>685</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">15276301</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munirajasekhar</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Himaja</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sunil</surname><given-names>VM.</given-names></name></person-group>
<article-title>Synthesis and anthelmintic activity of 2-amino-6- substituted benzothiazoles</article-title>. <source>Int Res J Pharm</source>
<year>2011</year>;<volume>2</volume>:<fpage>114</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Devprakash</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Senthilkumar</surname><given-names>GP.</given-names></name></person-group>
<article-title>Benzothiazole: different methods of synthesis and diverse biological activities</article-title>. <source>Int J Pharm Sci Drug Res</source>
<year>2011</year>;<volume>3</volume>:<fpage>01</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Rana</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>AS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of benzothiazole semicarbazones as novel anticonvulsants&#x02014;the role of hydrophobic domain</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2007</year>;<volume>17</volume>:<fpage>4178</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">17572089</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>HX</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of novel benzothiazole-2-thiol derivatives as potential anticancer agents</article-title>. <source>Molecules</source>
<year>2012</year>;<volume>17</volume>:<fpage>3933</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">22466853</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leong</surname><given-names>CO</given-names></name>, <name name-style="western"><surname>Suggitt</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Swaine</surname><given-names>DJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>In vitro, in&#x000a0;vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles</article-title>. <source>Mol Cancer Ther</source>
<year>2004</year>;<volume>3</volume>:<fpage>1565</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">15634650</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mortimer</surname><given-names>CG</given-names></name>, <name name-style="western"><surname>Wells</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Crochard</surname><given-names>JP</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Antitumor benzothiazoles. 26.1 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective Inhibitory activity against lung, colon, and breast cancer cell lines</article-title>. <source>J Med Chem</source>
<year>2006</year>;<volume>49</volume>:<fpage>179</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">16392802</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baffy</surname><given-names>G.</given-names></name></person-group>
<article-title>Hepatocellular carcinoma in type 2 diabetes: more than meets the eye</article-title>. <source>Am J Gastroenterol</source>
<year>2012</year>;<volume>107</volume>:<fpage>53</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">22218030</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>McCutcheon</surname><given-names>M.</given-names></name></person-group> Where have my eyebrows gone? Cengage learning. 2019. ISBN 07668393462001;5.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kunnumakara</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Sundaram</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cancer is a preventable disease that requires major lifestyle changes</article-title>. <source>Pharm Res</source>
<year>2008</year>;<volume>25</volume>:<fpage>2097</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">18626751</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumbhare</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Dadmal</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kosurkar</surname><given-names>U</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and cytotoxic evaluation of thiourea and N-bis-benzothiazolederivatives: a novel class of cytotoxic agents</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2012</year>; <volume>22</volume>:<fpage>453</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">22115593</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumbhare</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>VK</given-names></name>, <name name-style="western"><surname>Ramaiah</surname><given-names>JM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of novel Mannich bases of 2-arylimidazo[2,1- b]benzothi azoles as potential anti-cancer agents</article-title>. <source>Eur J Med Chem</source>
<year>2011</year>;<volume>46</volume>:<fpage>4258</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">21775028</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Damasy</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Seo</surname><given-names>HS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf<sup>V600E</sup> and C-Raf kinase inhibitory activities</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>115</volume>:<fpage>201</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">27017549</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of benzothiazole derivatives bearing theortho hydroxy- N &#x02013;acylhydrazone moiety as potent antitumor agents</article-title>. <source>Arch Pharm Chem Life Sci</source>
<year>2014</year>;<volume>347</volume>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabr</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>El-Gohary</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>El-Bendary</surname><given-names>RE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, in&#x000a0;vitro antitumor activity and molecular modeling studies 4 of a new series of benzothiazole Schiff bases</article-title>. <source>Chin Chem Lett</source>
<year>2016</year>;<volume>27</volume>:<fpage>380</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junjie</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Gang</surname><given-names>UH</given-names></name>, <name name-style="western"><surname>Lijun</surname><given-names>EIX</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and biological evaluation of novel benzothiazole derivatives bearing semicarbazone moiety as antitumor agents</article-title>. <source>Chem Res Chin Univ</source>
<year>2015</year>;<volume>31</volume>:<fpage>958</fpage>&#x02013;<lpage>63</lpage>.</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yurttas</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tay</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Demirayak</surname><given-names>S.</given-names></name></person-group>
<article-title>Synthesis and antitumor activity evaluation of new 2-(4-aminophenyl)benzothiazole derivatives bearing different heterocyclic rings</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2014</year>;<volume>30</volume>:<fpage>458</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">25198890</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kaur</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kaur</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>spectral studies and biological activity of 2, 3-disubstituted imidazo [2, 1-b] benzothiazole derivatives</article-title>. <source>Indian J Pharmaceut Biol Res</source>
<year>2018</year>;<volume>6</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Soud</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>Al-Sa&#x02019;doni</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>Saeed</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and in&#x000a0;vitro anti-proliferative activity of new benzothiazole derivatives</article-title>. <source>ARKIVOC</source>
<year>2008</year>;<volume>2008</volume>:<fpage>225</fpage>&#x02013;<lpage>238</lpage>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurdal</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Durmaz</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Atalay</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Yarim</surname><given-names>M.</given-names></name></person-group>
<article-title>Cytotoxic activities of some benzothiazole-piperazine derivatives</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2015</year>;<volume>30</volume>:<fpage>649</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">25333766</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhtar</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hameed</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Al-Masoudi</surname><given-names>AN</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>In vitro antitumor and antiviral activities of new benzothiazole and 1,3,4-oxadiazole-2-thione derivatives</article-title>. <source>Acta Pharm</source>
<year>2008</year>;<volume>58</volume>:<fpage>135</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">18515224</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeed</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rashid</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>GP</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, characterization and biological evaluation of some thiourea derivatives bearing benzothiazole moiety as potential antimicrobial and anticancer agents</article-title>. <source>Eur J Med Chem</source>
<year>2010</year>;<volume>45</volume>:<fpage>1323</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">20056520</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A novel benzothiazole derivative SKLB826 inhibits human hepatocellular carcinoma growth via inducing G2/M phase arrest and apoptosis</article-title>. <source>RSC Adv</source>
<year>2015</year>;<volume>5</volume>:<fpage>41341</fpage>.</mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Racane</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kulenovic</surname><given-names>TV</given-names></name>, <name name-style="western"><surname>Pavelic</surname><given-names>KS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel diamidino-substituted derivatives of phenyl benzothiazolyl and dibenzothia zolyl furans and thiophenes: synthesis, anti-proliferative and DNA binding properties</article-title>. <source>J Med Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>2418</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">20170096</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekar</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Perumal</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Arunachalam</surname><given-names>&#x000a0;</given-names></name>, <name name-style="western"><surname>Gandhimathi</surname><given-names>S.</given-names></name></person-group>
<article-title>Screening of anticancer activity in newly synthesized benzothiazole derivatives</article-title>. <source>J Pharm Sci Res</source>
<year>2011</year>;<volume>3</volume>:<fpage>1520</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xuejiao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yong</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ningyu</surname><given-names>W</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A novel benzothiazole derivative YLT322 induces apoptosis via the mitochondrial apoptosis pathway in&#x000a0;vitro with anti-tumor activity in solid malignancies</article-title>. <source>PLoS One</source>
<year>2013</year>;<volume>8</volume>:<fpage>e63900</fpage>.<pub-id pub-id-type="pmid">23737957</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ashraf</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vardhan</surname><given-names>VSP</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and anticancer potential of benzothiazole linked phenylpyridopyrimidinones and their diones as mitochondrial apoptotic inducers</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2014</year>;<volume>24</volume>:<fpage>147</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">24332497</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabr</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>El-Gohary</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>El-Bendary</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>El-Kerdawy</surname><given-names>MM.</given-names></name></person-group>
<article-title>Synthesis and in&#x000a0;vitro antitumor activity of new series ofbenzothiazole and pyrimido[2,1-b]benzothiazole derivatives</article-title>. <source>Euro J Med Chem</source>
<year>2014</year>;<volume>85</volume>:<fpage>576</fpage>&#x02013;<lpage>92</lpage>.</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumbhare</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Dadmal</surname><given-names>LT</given-names></name>, <name name-style="western"><surname>Devi</surname><given-names>AT</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Isoxazole derivatives of 6-fluoro-N-(6-methoxybenzo[d]thiazol-2-yl)benzo[d]thiazol-2-amine and N-(pyrimidin-2-yl)benzo[d]thiazol-2-amine: regulation of cell cycle and apoptosis by p53 activation via mitochondrial-dependent pathways</article-title>. <source>Med Chem Commun</source>
<year>2014</year>;<volume>5</volume>:<fpage>1744</fpage>.</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waghmare</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Chidrawar</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Bhosale</surname><given-names>NV</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and in-vitro anticancer activity of 3-cyano-6,9-dimethyl-4-imino 2-methylthio 4H-pyrimido [2,1-b] [1,3] benzothiazole and its 2-substituted derivative</article-title>. <source>J Pharm Res</source>
<year>2013</year>;<volume>7</volume>:<fpage>823</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caleta</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Kralj</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Marjanovic</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel cyano- and amidinobenzothiazole derivatives: synthesis, antitumor evaluation, and X-ray and quantitative structure-activity relationship (QSAR) analysis</article-title>. <source>J Med Chem</source>
<year>2009</year>;<volume>52</volume>:<fpage>1744</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">19265399</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osmaniye</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Levent</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Karaduman</surname><given-names>BA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of new benzothiazole acylhydrazones as anticancer agents</article-title>. <source>Molecules</source>
<year>2018</year>;<volume>23</volume>:<fpage>1054</fpage>.</mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lad</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Manohar</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Mascarenhas</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Methylsulfonyl benzothiazoles (MSBT) derivatives: search for new potential antimicrobial and anticancer agents</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2017</year>; <volume>27</volume>:<fpage>1319</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">28188067</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadhasivam</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kulanthai</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Natarajan</surname><given-names>A.</given-names></name></person-group>
<article-title>Synthesis and anti-cancer Studies of 2, 6-disubstituted benzothiazole derivatives</article-title>. <source>Orient J Chem</source>
<year>2015</year>;<volume>31</volume>:<fpage>819</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>HX</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, structure&#x02013;activity relationships and preliminary antitumor evaluation of benzothiazole-2-thiol derivatives as novel apoptosis inducers</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2011</year>;<volume>21</volume>:<fpage>1097</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">21262571</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolelli</surname><given-names>k</given-names></name>, <name name-style="western"><surname>Musdal</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Aki-Yalcin</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and activity mechanism of some novel 2-substituted benzothiazoles as hGSTP1-1 enzyme inhibitors</article-title>. <source>SAR QSAR Environ Res</source>
<year>2017</year>;<volume>28</volume>:<fpage>927</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">29206502</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Carocci</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Armenise</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Antiproliferative activity evaluation of a series of N-1,3-benzothiazol-2-ylbenzamides as novel apoptosis inducers</article-title>. <source>J Chem</source>
<year>2016</year>;<volume>5</volume>:<fpage>4267564</fpage>.</mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelgawad</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Lamie</surname><given-names>FP</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>MO.</given-names></name></person-group>
<article-title>Synthesis of new quinolone derivatives linked to benzothiazole or benzoxazole moieties as anticancer and anti-oxidant agents</article-title>. <source>Med Chem</source>
<year>2016</year>;<volume>6</volume>: <fpage>31</fpage>&#x02013;9.</mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Maiti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jadhav</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Paira</surname><given-names>P.</given-names></name></person-group>
<article-title>Benzothiazolylquinoline conjugates as novel human A3 receptor antagonists: biological evaluations and molecular docking studies</article-title>. <source>R Soc Open Sci</source>
<year>2018</year>;<volume>5</volume>:<fpage>171622</fpage>.<pub-id pub-id-type="pmid">29515874</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tay</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yurtta&#x0015f;</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Demirayak</surname><given-names>&#x0015e;.</given-names></name></person-group>
<article-title>Synthesis of some N-[4-(benzothiazole-2yl) phenyl]-2-aryloxyacetamide derivatives and their anticancer activities</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2012</year>;<volume>27</volume>:<fpage>515</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">21823837</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noolvi</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Kaur</surname><given-names>M.</given-names></name></person-group>
<article-title>Benzothiazoles: search for anticancer agents</article-title>. <source>Eur J Med Chem</source>
<year>2012</year>;<volume>54</volume>:<fpage>447</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">22703845</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Havrylyuk</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mosula</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zimenkovsky</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety</article-title>. <source>Eur J Med Chem</source>
<year>2010</year>;<volume>45</volume>:<fpage>5012</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">20810193</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prabhu</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Panneerselvam</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shastry</surname><given-names>SC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and anticancer evaluation of 2-phenyl thiaolidinone substituted 2-phenyl benzothiazole-6-carboxylic acid derivatives</article-title>. <source>J Saudi Chem Soc</source>
<year>2015</year>;<volume>19</volume>:<fpage>181</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelgawad</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Belal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>MO.</given-names></name></person-group>
<article-title>Synthesis, molecular docking studies and cytotoxic screening of certain novel thiazolidinone derivatives substituted with benzothiazole or benzoxazole</article-title>. <source>J Chem. pharm Sci</source>
<year>2013</year>;<volume>5</volume>:<fpage>318</fpage>&#x02013;<lpage>27</lpage>.</mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents</article-title>. <source>Eur J Med Chem</source>
<year>2015</year>;<volume>96</volume>:<fpage>173</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">25874341</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name></person-group>
<article-title>Benzothiazoles exhibit broad-spectrum antitumor activity: their potency, structure-activity and structure-metabolism relationships</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>76</volume>:<fpage>67</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">24576612</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uremis</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Uremis</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Tolun</surname><given-names>IF</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of 2-substituted benzothiazole derivatives and their in&#x000a0;vitro anticancer effects and antioxidant activities against pancreatic cancer cells</article-title>. <source>Anticancer Res</source>
<year>2017</year>;<volume>37</volume>:<fpage>6381</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29061823</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cindric</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Peric</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kralj</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Antibacterial and antiproliferative activity of novel 2-benzimidazolyland 2-benzothiazolyl-substituted benzo[b]thieno-2-carboxamides</article-title>. <source>Mol Divers</source>
<year>2018</year>;<volume>22</volume>:<fpage>637</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">29557543</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolova Momekov</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bakalova</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel Ru(III) complexes with some benzothiazole derivatives: synthesis, physicochemical and pharmacological investigations</article-title>. <source>Drug Res</source>
<year>2015</year>;<volume>65</volume>:<fpage>317</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yurttas</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cavusoglu</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Sever</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ciftci</surname><given-names>AG.</given-names></name></person-group>
<article-title>A preliminary investigation of anticanceractivity of novel benzothiazole derivatives against A549 lung carcinoma cell line</article-title>. <source>Turk J Biochem</source>
<year>2017</year>;<volume>42</volume>: <fpage>217</fpage>&#x02013;24.</mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oanh</surname><given-names>KTD</given-names></name>, <name name-style="western"><surname>Hai</surname><given-names>VH</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>HS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2011</year>;<volume>21</volume>:<fpage>7509</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">22036991</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Charris</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Camacho</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title><italic>N-</italic>Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies</article-title>. <source>J Pharm Pharmacol</source>
<year>2013</year>;<volume>65</volume>:<fpage>411</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">23356850</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Nagesh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Nayak</surname><given-names>LV</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of DNA-intercalative naphthalimide- benzothiazole/cinnamide derivatives: cytotoxicity evaluation and topoisomerase-II&#x003b1; inhibition</article-title>. <source>Med Chem Comm</source>
<year>2019</year>;<volume>10</volume>:<fpage>72</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>SVA</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>Sunkari</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>2-Arylaminobenzothiazole-arylpropenone conjugates as tubulin polymerization inhibitors</article-title>. <source>Med Chem Commun</source>
<year>2017</year>;<volume>8</volume>:<fpage>924</fpage>&#x02013;<lpage>41</lpage>.</mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osmaniye</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Levent</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ard&#x00131;c</surname><given-names>MC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and anticancer activity of some novel benzothiazolethiazolidine derivatives</article-title>. <source>Phosphorus Sulfur</source>
<year>2018</year>;<volume>193</volume>:<fpage>249</fpage>&#x02013;<lpage>56</lpage>.</mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrases: novel therapeutic applications for inhibitors and activators</article-title>. <source>Nature Rev Drug Discov</source>
<year>2008</year>;<volume>7</volume>:<fpage>168</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">18167490</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Structure and function of carbonic anhydrases</article-title>. <source>Biochem J</source>
<year>2016</year>;<volume>473</volume>:<fpage>2023</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27407171</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>How many carbonic anhydrase inhibition mechanisms exist?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>345</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26619898</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neri</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Interfering with pH regulation in tumours as a therapeutic strategy</article-title>. <source>Nat Rev Drug Discov</source>
<year>2011</year>;<volume>10</volume>:<fpage>767</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">21921921</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrases and metabolism</article-title>. <source>Metabolites</source>
<year>2018</year>;<volume>8</volume>:<fpage>pii:E25</fpage>.</mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibition and the management of hypoxic tumors</article-title>. <source>Metabolites</source>
<year>2017</year>;<volume>7</volume>:pii:E48.</mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Advances in structure-based drug discovery of carbonic anhydrase inhibitors</article-title>. <source>Expert Opin Drug Discov</source>
<year>2017</year>;<volume>12</volume>:<fpage>61</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">27783541</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas</article-title>. <source>Expert Opin Ther Pat</source>
<year>2018</year>;<volume>28</volume>:<fpage>709</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">30217119</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases</article-title>. <source>Expert Opin Ther Pat</source>
<year>2018</year>;<volume>28</volume>:<fpage>713</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">30175635</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery</article-title>. <source>Expert Opin Drug Discov</source>
<year>2019</year>;<volume>14</volume>:<fpage>1175</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">31436118</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Simone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>(In)organic anions as carbonic anhydrase inhibitors</article-title>. <source>J Inorg Biochem</source>
<year>2012</year>;<volume>111</volume>:<fpage>117</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">22192857</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors</article-title>. <source>Expert Opin Investig Drugs</source>
<year>2018</year>;<volume>27</volume>:<fpage>963</fpage>&#x02013;<lpage>70</lpage>.</mixed-citation></ref><ref id="CIT0079"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tars</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kazaks</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sulfocoumarins (1,2-benzoxathiine 2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases</article-title>. <source>J Med Chem</source>
<year>2013</year>;<volume>56</volume>:<fpage>293</fpage>&#x02013;<lpage>300</lpage>.<pub-id pub-id-type="pmid">23241068</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#x000f6;hler</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hillebrecht</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schulze Wischeler</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste</article-title>. <source>Angew Chem Int Ed Engl</source>
<year>2007</year>;<volume>46</volume>:<fpage>7697</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17705204</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Ilies</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors. Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives</article-title>. <source>Eur J Med Chem</source>
<year>1998</year>;<volume>33</volume>:<fpage>739</fpage>&#x02013;<lpage>52</lpage>.</mixed-citation></ref><ref id="CIT0082"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sent&#x000fc;rk</surname><given-names>M</given-names></name>, <name name-style="western"><surname>G&#x000fc;l&#x000e7;in</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Da&#x0015f;tan</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols</article-title>. <source>Bioorg Med Chem</source>
<year>2009</year>;<volume>17</volume>:<fpage>3207</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">19231207</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008&#x02013;2018)</article-title>. <source>Expert Opin Ther Pat</source>
<year>2018</year>;<volume>28</volume>:<fpage>729</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">30074415</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Fiore</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pedone</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Antel</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2008</year>;<volume>18</volume>:<fpage>2669</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">18359629</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>SitaRam</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Khloya</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>4-Functionalized 1,3-diarylpyrazoles bearing 6-aminosulfonylbenzothiazole moiety as potent inhibitors of carbonic anhydrase isoforms hCA I, II, IX and XII</article-title>. <source>Bioorg Med Chem</source>
<year>2014</year>;<volume>22</volume>:<fpage>6945</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">25456084</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Lasheen</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Zaky</surname><given-names>MY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of benzothiazole-6-sulfonamides acting as highly potent inhibitors of carbonic anhydrase isoforms I, II, IX and XII</article-title>. <source>Bioorg Med Chem</source>
<year>2015</year>;<volume>23</volume>:<fpage>4989</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">26048024</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#x000fc;&#x000e7;&#x000fc;kbay</surname><given-names>FZ</given-names></name>, <name name-style="western"><surname>Bu&#x0011f;day</surname><given-names>N</given-names></name>, <name name-style="western"><surname>K&#x000fc;&#x000e7;&#x000fc;kbay</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, characterization and carbonic anhydrase inhibitory activity of novel benzothiazole derivatives</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>1221</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">26598927</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Geronikaki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Terzi</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of carbonic anhydrase isoforms I, II, IX and XII with secondary sulfonamides incorporating benzothiazole scaffolds</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>1306</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">26745009</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Payaz</surname><given-names>D&#x000dc;</given-names></name>, <name name-style="western"><surname>K&#x000fc;&#x000e7;&#x000fc;kbay</surname><given-names>FZ</given-names></name>, <name name-style="western"><surname>K&#x000fc;&#x000e7;&#x000fc;kbay</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis carbonic anhydrase enzyme inhibition and antioxidant activity of novel benzothiazole derivatives incorporating glycine, methionine, alanine, and phenylalanine moieties</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>343</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30734592</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammazzalorso</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Fibrate-based N-acylsulphonamides targeting carbonic anhydrases: synthesis, biochemical evaluation, and docking studies</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>1051</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">31074307</pub-id></mixed-citation></ref><ref id="CIT0091"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdoli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bozdag</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo[d]thiazole-5- and 6-sulfonamides</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>1071</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28753093</pub-id></mixed-citation></ref><ref id="CIT0092"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alterio</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Esposito</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Monti</surname><given-names>SM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Crystal structure of the human carbonic anhydrase II adduct with 1-(4-sulfamoylphenyl-ethyl)-2,4,6-triphenylpyridinium perchlorate, a membrane-impermeant, isoform selective inhibitor</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>151</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">29199489</pub-id></mixed-citation></ref><ref id="CIT0093"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbon-versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>485</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">29390912</pub-id></mixed-citation></ref><ref id="CIT0094"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pustenko</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Stepanovs</surname><given-names>D</given-names></name>, <name name-style="western"><surname>&#x0017d;alubovskis</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>3H-1,2-benzoxathiepine 2,2-dioxides: a new class of isoform-selective carbonic anhydrase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>767</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">28537099</pub-id></mixed-citation></ref><ref id="CIT0095"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramya</surname><given-names>PVS</given-names></name>, <name name-style="western"><surname>Angapelly</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of curcumin inspired sulfonamide derivatives as a new class of carbonic anhydrase isoforms I, II, IX, and XII inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>1274</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">28965419</pub-id></mixed-citation></ref><ref id="CIT0096"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akocak</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lolak</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bua</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Discovery of novel 1,3-diaryltriazene sulfonamides as carbonic anhydrase I, II, VII, and IX inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>1575</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">30296852</pub-id></mixed-citation></ref><ref id="CIT0097"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Gazzar</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Nafie</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibition with a series of novel benzenesulfonamide-triazole conjugates</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>1565</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">30274535</pub-id></mixed-citation></ref><ref id="CIT0098"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Ascenzio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Guglielmi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Carradori</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>51</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27784170</pub-id></mixed-citation></ref><ref id="CIT0099"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Menabuoni</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mincione</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action</article-title>. <source>J Med Chem</source>
<year>2000</year>;<volume>43</volume>:<fpage>4542</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">11087579</pub-id></mixed-citation></ref><ref id="CIT0100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Briganti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Mincione</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route</article-title>. <source>J Med Chem</source>
<year>1999</year>;<volume>42</volume>:<fpage>3690</fpage>&#x02013;<lpage>700</lpage>.<pub-id pub-id-type="pmid">10479300</pub-id></mixed-citation></ref><ref id="CIT0101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Clare</surname><given-names>BW.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors. Part 57. Quantum chemical QSAR of a group of 1,3,4-thiadiazole and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties</article-title>. <source>Eur J Med Chem</source>
<year>1999</year>;<volume>34</volume>:<fpage>41</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation></ref><ref id="CIT0102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Nicolae</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Popescu</surname><given-names>A.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors. Part 35. Synthesis of Schiff bases derived from sulfanilamide and aromatic aldehydes: the first inhibitors with equally high affinity towards cytosolic and membrane-bound isozymes</article-title>. <source>Eur J Med Chem</source>
<year>1996</year>;<volume>31</volume>:<fpage>431</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarikaya</surname><given-names>SB&#x000d6;</given-names></name>, <name name-style="western"><surname>Topal</surname><given-names>F</given-names></name>, <name name-style="western"><surname>&#x0015e;ent&#x000fc;rk</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>In vitro inhibition of &#x003b1;-carbonic anhydrase isozymes by some phenolic compounds</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2011</year>;<volume>21</volume>:<fpage>4259</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">21669522</pub-id></mixed-citation></ref></ref-list></back></article>